Related Experiment Videos
[Clinical studies of cefodizime in the pediatric field]
Insights
Cefodizime (CDZM) demonstrates favorable pharmacokinetics and a high efficacy rate of 89.7% in pediatric patients with bacterial infections. This injectable antibiotic showed good safety with minimal side effects, suggesting its effectiveness in children.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antibiotic Therapy
Background:
- Bacterial infections pose a significant health risk in pediatric populations.
- Effective and safe antibiotic options are crucial for treating childhood infections.
- Cefodizime (CDZM) is an injectable antibiotic requiring evaluation in pediatric patients.
Observation:
- Pharmacokinetic parameters including serum half-life and urinary excretion were determined for CDZM in children.
- Clinical efficacy was assessed in 29 pediatric patients across various infection types, including respiratory and urinary tract infections.
- Pathogen eradication rates and clinical outcomes were analyzed in patients with identified causative agents.
Findings:
- Cefodizime exhibited mean serum half-lives of approximately 115-120 minutes and high urinary excretion rates (around 75%).
- An overall clinical efficacy rate of 89.7% was observed, with excellent or good responses in 13 and 13 patients, respectively.
- Pathogen eradication was achieved in 60% of cases, with 100% excellent or good clinical efficacy when pathogens were identified.
Implications:
- Cefodizime demonstrates favorable pharmacokinetic properties and a strong safety profile in pediatric patients.
- The high efficacy rates suggest CDZM is a valuable therapeutic option for treating bacterial infections in children.
- Further research may support the expanded use of Cefodizime in pediatric infectious disease management.
Abstract:
Cefodizime (CDZM, THR-221) was evaluated for its pharmacokinetics, safety and efficacy in 30 pediatric patients with bacterial infections. The following results were obtained. 1. The pharmacokinetics of CDZM in 6 children were investigated with a dose level of 20 mg/kg via intravenous injection. Mean serum half-lives (T 1/2 beta) of the drug were 120.9 minutes (HPLC) and 115.6 minutes (bioassay). In 8 hours after administration of CDZM, urinary excretion rates were 74.7% (HPLC) and 75.0% (bioassay). 2. The clinical efficacies of CDZM were studied in 29 pediatric patients, comprising 22 with respiratory tract infections, 2 with urinary tract infections, 2 with enteritis, 2 with lymphadenitis and 1 with gingivitis. The clinical efficacies were excellent in 13, good in 13 and fair in 3, with an efficacy rate of 89.7%. 3. The eradication rate for pathogens identified in 7 pediatric patients was 60% (6/10). The clinical efficacy rate in cases where pathogens were identified was 100% in terms of excellent+ good evaluations. 4. Only one case of mild diarrhea was observed as a side effect associated with CDZM. Laboratory tests revealed abnormal value of slightly elevated eosinophil in 3 cases. The data suggested that CDZM is a safe and effective injectable antibiotic for the treatment of infections in children.